Skip to content

Randomized Double-Blind Clinical Study on the Treatment of Chronic Atrophic Gastritis with Qilian Xiaopi Decoction

Randomized Double-Blind Clinical Study on the Treatment of Chronic Atrophic Gastritis with Qilian Xiaopi Decoction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000243
Enrollment
Unknown
Registered
2026-02-03
Start date
2025-05-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic atrophic gastritis

Interventions

control group:Administer placebo granules (5% active ingredient plus maltodextrin, etc.), taken as granules dissolved in water, 1 dose per day, twice daily
the treatment course is 24 weeks.
Traditional Chinese Medicine group :Administer Qilian Xiaopi traditional Chinese medicine formula granules taken as granules dissolved in water 1 dose per day twice daily

Sponsors

Wangjing Hospital China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for chronic atrophic gastritis in Western medicine and the diagnostic criteria for spleen deficiency and qi stagnation syndrome in traditional Chinese medicine; (2) HP-negative patients; (3) Pathological examination by gastroscopy before enrollment shows atrophy (reduction of the inherent glands) with or without intestinal metaplasia without mild or moderate dysplasia; (4) Aged between 35 and 70 years regardless of gender; (5) Subjects are informed and voluntarily sign the informed consent form; (6) Permanent residents of the local area able to ensure treatment follow-up; (7) No use of anticoagulants and no coagulation function disorders.

Exclusion criteria

Exclusion criteria: (1) Patients with concomitant peptic ulcers or upper gastrointestinal bleeding; (2) Patients with high-grade intraepithelial neoplasia of the gastric mucosa or pathological diagnosis suggestive of malignancy; (3) Patients with severe primary diseases; (4) Pregnant or breastfeeding women (female participants must take contraceptive measures); (5) Patients with psychiatric disorders; (6) Individuals with potential allergies to the study drug; (7) Situations deemed inappropriate for enrollment by the researcher; (8) Patients currently participating in other drug clinical trials.

Design outcomes

Primary

MeasureTime frame
Patient Self-Reported Symptom Intensity via Visual Analog Scale (VAS);

Secondary

MeasureTime frame
Three gastric functions;Traditional Chinese Medicine Syndrome Differentiation Scale (TCM-SDS);OLGIM and OLGA scoring criteria;

Countries

China

Contacts

Public ContactTao Liu

Wangjing Hospital China Academy of Chinese Medical Sciences

ltlyf2@163.com13521218699

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 14, 2026